XTL licenses development rights to pain therapy

XTL Biopharmaceuticals has agreed to pay $7.5 million upfront and up to $126.5 million in cash and shares to DOV Pharmaceutical to license development rights to bicifadine as a treatment for neuropathic pain. Bicifadine has been evaluated in 15 clinical trials, including two trials in patients suffering from acute (non-neuropathic) pain, where Bicifadine demonstrated statistically significant efficacy.

- see the release on the licensing pact

Related Articles
DOV formulates new development strategy. Report
DOV CEO resigns in shakeup. Report

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.